Best Practices: The Evolving Commercial Genomics IT Landscape
|Author:||Alan S. Louie, Ph.D.|
|Document Type||Best Practices|
|Number of Pages||15|
This IDC Health Insights report highlights the impending arrival of the $1,000 genome and its likely impact on transforming the life science industry forever. With a detailed view of leading trends as well as the current leading technology, IT, and informatics innovators supporting progress in this increasingly important space, we hope to provide readers with a snapshot of where we are and the likely players that will help drive future progress from both a general IT and an industry-specific vendor perspective. While much remains left to be learned, we are clearly on a path forward that should enable improved patient outcomes from a more personalized medicine–based future.
"While genomics may eventually be found to have only a supporting role in the manifestation of many human diseases, the advent of the age of genomics will still transform the life science and healthcare industries by accelerating progress in our understanding of human biology at the molecular level," says Alan S. Louie, research director, IDC Health Insights.
FedEx Corporation, PerkinElmer, Inc., CLC bio, Accelrys, Inc., Strand Life Sciences Pvt. Ltd., Illumina, Inc., Ion Torrent Systems, Inc., NextBio, Roche Holding AG, DNANEXUS INC., Oxford Nanopore Ltd., Oracle Corporation, Biomatters Ltd., Tata Consultancy Services Limited, Omixon, GenomeQuest, Inc.
Applications, Big Data analytics and discovery, Databases, Hardware, InfiniBand switching, Market intelligence, Network-attached storage, Networks, Parallel and distributed file systems, Public cloud services, Scalable hardware, Software, Storage, Tape storage
Our records show that you do not have access to this document.